dc.contributor.author | Chopra, Sidharth | |
dc.date.accessioned | 2014-04-21T09:38:29Z | |
dc.date.available | 2014-04-21T09:38:29Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Future Microbiology, 2013; 8(8), 951-2. | en |
dc.identifier.uri | http://hdl.handle.net/123456789/1204 | |
dc.format.extent | 36284 bytes | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en | en |
dc.relation.ispartofseries | CSIR-CDRI Communication No. 8484 | en |
dc.subject | FDA approved drugs | en |
dc.subject | Repurposing | en |
dc.subject | Mycobacterium | en |
dc.subject | Acinetobacter | en |
dc.subject | Ebola | en |
dc.subject | Fungi | en |
dc.title | ‘Could repurposing existing drugs be an efficient protective method against microbial biologic threats?’ | en |
dc.type | Article | en |